Engrail closes $157M series B, fueled by investors' renewed interest in neuropsychiatry

Engrail Therapeutics has closed a nine-digit series B to further its neuropsychiatric pipeline, the latest evidence that investors are flocking to fund new treatments in this resurgent therapeutic area.